Table 2. Correlation between the status of the miR-31 host gene locus and pathologic subjects.

Subjects	FISH score
*Histology (127)
ADC (71)	0.706±0.303
*Grade
WEL (47)	0.759±0.297
MOD (8)	0.787±0.316
POR (16)	0.511±0.262
*Subtype
BAC (36)	0.766±0.302
ACI (12)	0.663±0.321
PAP (3)	0.762±0.253
SOL (12)	0.459±0.273
MUC (8)	0.851±0.212
SQC (38)	0.658±0.395
Grade
WEL (0)	-
MOD (34)	0.649±0.415
POR (4)	0.736±0.145
LCC (18)	3.236±3.298
BRE (30) reference	1.007±0.130
Vascular involvement (127)
Present (30)	0.872±0.916
Absent (97)	1.626±2.650
Lymphatic canal involvement (127)
Present (25)	1.499±2.589
Absent (102)	0.941±1.135
Lymph node metastasis (114)
Present (10)	0.706±0.341
Absent (104)	0.630±0.345
MIB1 labeling index (127)
Low level (<10%) (36)	1.187±1.789
High level (≥10%) (91)	0.706±0.313
Oncogenic mutation (111)
KRAS (5)	0.723±0.189
EGFR (22)	0.805±0.213
NONE (84)	0.662±0.382

*Significant in a one-way ANOVA analysis; BRE versus ADC, P<0.0001; BRE versus SQC, P<0.0001; BRE versus LCC, P = 0.0008; ADC/WEL versus ADC/POR, P = 0.0049; ADC/MOD versus ADC/POR, P = 0.0332; BAC versus SOL, P = 0.0013; PAP versus SOL, P = 0.0433; MUC versus SOL, P = 0.0007; ADC, adenocarcinoma; SQC, squamous cell carcinoma; LCC, large cell carcinoma; BRE, bronchial epithelia; WEL, well differentiated; MOD, moderately differentiated; POR, poorly differentiated carcinomas; BAC, bronchioloalveolar carcinoma; ACI, acinar adenocarcinoma; PAP, papillary adenocarcinoma; SOL, solid adenocarcinoma; MUC, mucinous adenocarcinoma; NONE, cases without KRAS or EGFR mutations.